AccessPak for HIV PEP Expanded with Kaletra Interactions
There are 911 drugs known to interact with AccessPak for HIV PEP Expanded with Kaletra (emtricitabine/lopinavir/ritonavir/tenofovir disoproxil), along with 12 disease interactions, and 5 alcohol/food interactions. Of the total drug interactions, 400 are major, 482 are moderate, and 29 are minor.
- View all 911 medications that may interact with AccessPak for HIV PEP Expanded with Kaletra
- View AccessPak for HIV PEP Expanded with Kaletra alcohol/food interactions (5)
- View AccessPak for HIV PEP Expanded with Kaletra disease interactions (12)
Most frequently checked interactions
View interaction reports for AccessPak for HIV PEP Expanded with Kaletra (emtricitabine / lopinavir / ritonavir / tenofovir disoproxil) and the medicines listed below.
- BeneFix (coagulation factor ix)
- Bexxar (iodine i 131 tositumomab)
- Eldepryl (selegiline)
- Enbrel (etanercept)
- Imbruvica (ibrutinib)
- Imuran (azathioprine)
- Integrilin (eptifibatide)
- Iodotope (sodium iodide-i-131)
- Kalydeco (ivacaftor)
- Klonopin (clonazepam)
- Moderiba (ribavirin)
- Namenda (memantine)
- NovoSeven RT (coagulation factor viia)
- Pegasys (peginterferon alfa-2a)
- Prandin (repaglinide)
- Prexxartan (valsartan)
- Procysbi (cysteamine)
- Prograf (tacrolimus)
- Provenge (sipuleucel-T)
- Pulmozyme (dornase alfa)
- raxibacumab
- Rebif Rebidose (interferon beta-1a)
- ReoPro (abciximab)
- Soliris (eculizumab)
- Stivarga (regorafenib)
- Stribild (cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil)
- strontium-89 chloride
- Tracleer (bosentan)
- Viekira Pak (dasabuvir / ombitasvir / paritaprevir / ritonavir)
- Vosevi (sofosbuvir / velpatasvir / voxilaprevir)
AccessPak for HIV PEP Expanded with Kaletra alcohol/food interactions
There are 5 alcohol/food interactions with AccessPak for HIV PEP Expanded with Kaletra (emtricitabine / lopinavir / ritonavir / tenofovir disoproxil).
AccessPak for HIV PEP Expanded with Kaletra disease interactions
There are 12 disease interactions with AccessPak for HIV PEP Expanded with Kaletra (emtricitabine / lopinavir / ritonavir / tenofovir disoproxil) which include:
- hepatitis B
- hepatotoxicity
- hemodialysis
- renal dysfunction
- hemophilia
- hyperglycemia
- hyperlipidemia
- heart block
- hepatotoxicity
- bone toxicity
- liver disease
- renal dysfunction
Report options
More about AccessPak for HIV PEP Expanded with Kaletra (emtricitabine / lopinavir / ritonavir / tenofovir disoproxil)
- AccessPak for HIV PEP Expanded with Kaletra consumer information
- Compare alternatives
- Side effects
- Drug class: antiviral combinations
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.